echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > The investigative Alzheimer's disease treatment LECANEMAB was designated by the U.S. FDA for fast-track application

    The investigative Alzheimer's disease treatment LECANEMAB was designated by the U.S. FDA for fast-track application

    • Last Update: 2022-01-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    <>


    In September 2021, Eisai began rolling submission of lecanemab's Biologics Licensing Application (BLA) to the FDA according to the accelerated approval channel


    The phase 3 clinical study of lecanemab Clarity AD for early AD is underway, and recruitment was completed in March 2021, with a total of 1,795 patients


    Alzheimer's disease is a serious, progressive, and devastating disease with few treatment options


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.